Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | PARP1 | P09874 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.41 |
| ▸ | CDK4 | P11802 | 2/20 | 0.41 |
| ▸ | CCND1 | P24385 | 2/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | CAMK2B | Q13554 | 2/20 | 0.41 |
| ▸ | CAMK2G | Q13555 | 2/20 | 0.41 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.41 |
| ▸ | CAMK2A | Q9UQM7 | 2/20 | 0.41 |
| ▸ | IDH1 | O75874 | 1/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25173200 | 0.83 | GRIN2D (0.52) | CA12CA9PARP1KDM4EAHR | |
| SCHEMBL31638993 | 0.76 | IDH1 (0.52) | CA12CA9PARP1KDM4EIDH1 | |
| SCHEMBL11385706 | 0.76 | KDM4E (0.43) | CA12CA9PARP1KDM4EPDE3B | |
| SCHEMBL763349 | 0.76 | GRIA1 (0.52) | CA12CA9PARP1KDM4EAHR | |
| SCHEMBL2731038 | 0.75 | PARP1 (0.48) | CA12CA9PARP1KDM4ECCNE2 | |
| SCHEMBL1502649 | 0.75 | FEN1 (0.50) | CA12CA9PARP1KDM4EAHR | |
| SCHEMBL30013511 | 0.75 | FEN1 (0.50) | CA12CA9PARP1KDM4EAHR | |
| SCHEMBL6367421 | 0.74 | KDM4E (0.42) | CA12CA9PARP1KDM4EPDE3B | |
| SCHEMBL2483323 | 0.74 | POLB (0.52) | CA12CA9PARP1KDM4EPDE3B | |
| SCHEMBL22619216 | 0.74 | KDM4E (0.42) | CA12CA9PARP1KDM4EPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4608988-A1 | CLOSED-LOOP OPTIMIZATION OF GENERAL REACTION CONDITIONS FOR HETEROARYL SUZUKI-MIYAURA COUPLING | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-09-03 | — | — | EP | disclosed |
| WO-2024243025-A1 | NAPHTHYL-SUBSTITUTED PYRIDO[4,3-D]PYRIMIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | Ikena Oncology, Inc. (US) | 2024-11-28 | — | — | WO | disclosed |
| WO-2024149189-A1 | AROMATIC AMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 浙江海正药业股份有限公司 | 2024-07-18 | — | — | WO | disclosed |
| WO-2024127297-A1 | 3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF | PFIZER INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| CN-112074511-B | Substituted benzodiazoles and their use in therapy | 托马斯·黑勒戴药物研究基金会 | 2024-04-26 | — | — | CN | disclosed |
| US-20220127281-A1 | HETEROARYL COMPOUNDS THAT INHIBIT G12C MUTANT RAS PROTEINS | ASTRAZENECA UK LIMITED (GB) | 2022-04-28 | — | — | US | disclosed |
| WO-2021237111-A1 | NOTCH INHIBITORS AND USES THEREOF | STEMSYNERGY THERAPEUTICS, INC. (US) | 2021-11-25 | — | — | WO | disclosed |
| US-20200109153-A1 | HETEROARYL COMPOUNDS THAT INHIBIT G12C MUTANT RAS PROTEINS | ASTRAZENECA AB (SE) | 2020-04-09 | — | — | US | disclosed |
| US-10174052-B2 | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-08 | — | — | US | disclosed |
| US-10174052-B2 | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-01-08 | — | — | US | disclosed |
| US-20170305929-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-26 | — | — | US | disclosed |
| EP-3215512-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Bristol-Myers Squibb Company (US) | 2017-09-13 | — | — | EP | disclosed |
| WO-2016073407-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-12 | — | — | WO | disclosed |
| WO-2016073407-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-12 | — | — | WO | disclosed |
| US-20110081315-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| WO-2011038293-A1 | CYCLIC PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| EP-2271649-A1 | BRIDGED, BICYCLIC HETEROCYCLIC OR SPIRO BICYCLIC HETEROCYCLIC DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINES, METHODS FOR PREPARATION AND USES THEREOF | Wyeth LLC (US) | 2011-01-12 | — | — | EP | disclosed |
| US-20100029657-A1 | Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof | WYETH (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2009111260-A1 | PHENYLSULFONAMIDE-SUBSTITUTED, PYRAZOLO[1, 5-A]PYRIMIDINES, METHODS FOR PREPARATION AND USES THEREOF | WYETH (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009108838-A1 | BRIDGED, BICYCLIC HETEROCYCLIC OR SPIRO BICYCLIC HETEROCYCLIC DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINES, METHODS FOR PREPARATION AND USES THEREOF | WYETH (US) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174052-B2 | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands | CHRNA7, CHRNA5, CHRNA2 | CA12 2644/4885CA9 2566/4885PARP1 3112/4885 |
| US-20200109153-A1 | HETEROARYL COMPOUNDS THAT INHIBIT G12C MUTANT RAS PROTEINS | KRAS, NRAS, HRAS | CA12 4783/4885CA9 4177/4885PARP1 3784/4885 |
| US-20220127281-A1 | HETEROARYL COMPOUNDS THAT INHIBIT G12C MUTANT RAS PROTEINS | KRAS, NRAS, HRAS | CA12 4752/4885CA9 4221/4885PARP1 3896/4885 |
| US-20100029657-A1 | Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof | BRAF, RAF1, ARAF | CA12 4755/4885CA9 3223/4885PARP1 1664/4885 |
| US-20110081315-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, EIF4A2 | CA12 3735/4885CA9 2807/4885PARP1 805/4885 |
| US-20170305929-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA2 | CA12 2312/4885CA9 2419/4885PARP1 3304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.